Thursday Sessions Evaluations Logo

  • Thursday Sessions Evaluations

    Psychedelic Science 2025

  • Instructions

  • Use this form to complete evaluations for each workshop you attended. 

    • Pages are linked in tabs at the top of this page.
    • You can save the form and return to it at any time. When you save the form, you will be prompted to either create an account using your email address or sign up with Google. Alternatively, you can skip creating an account and copy your unique form link. If you create an account, you will receive an email to verify your account and a second email with your form link. Either option will save your progress.
    • Please complete (submit) only one form per person by July 4, 2025.

  • Learner Information

  • Thursday, June 19

    • Studying The Study Of Psychedelic-Assisted Therapy 

    • At the end of the session, the learner will be able to:

      1. Discuss the challenges and opportunities in the field of psychedelic drug development.

      2. Describe recommendations for future psychedelic drug development programs based on lessons learned to date will be reviewed.

    • Breaking Barriers On The Path To Liberation: A Call To Center Black Women’s Healing Journey 

    • At the end of the session, the learner will be able to:

      1. Describe how the liberation of Black women, both in and around the psychedelic space, contributes to broader collective liberation.

      2. Explain of the impact of spirituality and community on Black women’s mental health and be able to develop culturally informed support strategies.

    • Long COVID And Psychedelics: Lessons From Care Providers And Early Data 

    • At the end of the session, the learner will be able to:

      1. Evaluate the potential therapeutic applications of psychedelic-assisted therapy for healthcare providers experiencing burnout, trauma, or psychological distress in the context of long COVID.

      2. Analyze current evidence and clinical considerations for integrating psychedelic-assisted interventions in the treatment of persistent neuropsychiatric and somatic symptoms associated with long COVID.

    • Studies Of Anxiety, OCD, And Eating Disorders Using Psychedelic-Assisted Therapy 

    • At the end of the session, the learner will be able to:

      1. Describe the need for more treatment outcome research on social anxiety disorder.

      2. Recite the primary outcomes and safety data for MDMA-AT for social anxiety disorder.

    • Healing Together: Ketamine-Assisted Psychotherapy In A Community-Centered Model 

    • At the end of the session, the learner will be able to:

      1. Describe the therapeutic benefits and mechanisms of group-based Ketamine-Assisted Psychotherapy (KAP) within community-centered models.

      2. Identify key clinical and ethical considerations in implementing group KAP protocols across diverse communities.

    • Improving Standardization And Reducing Bias In Psychedelic Drug Development Trials Using An AI-Enabled Platform 

    • At the end of the session, the learner will be able to:

      1. Discuss the importance of fidelity monitoring in clinical trials.

      2. Assess the application of an AI system to improve quality oversight of psychedelic clinical trials.

    • Psychedelics And Societies In Crisis 

    • At the end of the session, the learner will be able to:

      1. Describe how war induced PTSD affects subsequent generations.

      2. Describe how community healing works and when it doesn't.

    • Studies Of Gender, Sexuality, And Psychedelics 

    • At the end of the session, the learner will be able to:

      1. Describe the mental health disparities experienced by gender and sexual minority (GSM) individuals and how psychedelic experiences may influence symptoms of depression, anxiety, and traumatic stress.

      2. Identify the potential impacts of psychedelic experiences on gender and sexual identity development among GSM individuals, including mental health conditions, self-acceptance, and identity exploration.

    • Treating Pain And Neurological Disorders With Psychedelic-Assisted Therapy 

    • At the end of the session, the learner will be able to:

      1. Describe the design and key outcomes of the recent randomized, double-blind pilot trial (NCT05224336) assessing psilocybin in individuals with PLP, focusing on safety, feasibility, and pain-related endpoints.

      2. Explain the clinical significance of reductions in residual and phantom limb pain following psilocybin administration, and the observed relationship between resting-state brain connectivity and treatment outcomes.

    • Unlocking The Science Of Psychedelic-Induced Neuroplasticity 

    • At the end of the session, the learner will be able to:

      1. Explain the modern analytical and biotechnological methods—such as NMR spectroscopy and mass spectrometry—used for characterizing and standardizing psychedelic compounds, including substituted tryptamines.

      2. Discuss how non-clinical rodent can inform human clinical trials.

      3. Explain how psilocybin evokes plasticity differently across brain cell types.

      4. Describe how neuron activity during psychedelic exposure may or may not be related to long-term plasticity.

    • Frontiers In Psilocybin Research For OCD: Neural Mechanisms, Treatment Response, And Clinical Implications 

    • At the end of the session, the learner will be able to:

      1. Describe the clinical rationale, safety profile, and trial design for investigating single-dose psilocybin as a treatment for obsessive-compulsive disorder (OCD), with emphasis on its implementation in a randomized, double-blind, placebo-controlled study and the underlying theoretical model of action.

      2. Identify key psychological and neurobiological mechanisms of therapeutic change following psilocybin administration in individuals with treatment-resistant OCD, and evaluate how subjective psychedelic experiences relate to symptom improvement.

       

    • High Impact: Perspectives On Empowered Psychedelic Healing From Sexual Violence 

    • At the end of the session, the learner will be able to:

      1. Identify somatic elements in psychedelic healing within a clinical context.

      2. Discuss the spiritual impacts of sexual violence and their relationship to psychedelic healing.

    • Studies Of Women, Female Biology, And Psychedelics 

    • At the end of the session, the learner will be able to:

      1. Describe the intentions, practices, perceived risks, and benefits of naturalistic psilocybin use among mothers.

      2. Discuss how mothers use affects parenting, mental health, and substance use disorders.

    • Beyond The Blobs: Critical Perspectives On Visualizing The Psychedelic Brain 

    • At the end of the session, the learner will be able to:

      1. Identify what different brain imaging techniques actually represent in terms of underlying data.

      2. Explain the functional and scientific choices implicit in different imaging techniques or representations.

    • Studies Of Couples, Couples Therapy, And Psychedelics 

    • At the end of the session, the learner will be able to:

      1. Describe the first preliminary data on couples, psilocybin and relationship wellbeing with psychological support.

      2. Discuss methods of psilocybin-assisted relationship therapy for couples.

    • The Library Is Open: A Conversation About Queer-Affirming Psychedelic Therapy 

    • At the end of the session, the learner will be able to:

      1. Assess barriers toward queer-affirming psychedelic therapy.

      2. Identify principles of queer-affirming psychedelic therapy.

    • Transdiagnostic Outcomes From Yale's Real-World Psilocybin Trial: Connecticut-Funded Pioneering Psychedelic Therapy Program And Insights From Other State Initiatives 

    • At the end of the session, the learner will be able to:

      1. Describe the regulatory and operational challenges encountered when implementing a transdiagnostic psilocybin clinical trial protocol at an academic medical center, including DEA licensing, FDA requirements, and infrastructure considerations.

      2. Explain the methodological approach to measuring cognitive flexibility as a potential transdiagnostic mechanism of psilocybin's effects, including selection of appropriate behavioral tasks and analytical strategies.

    • Neuroimaging Research Updates From Imperial College 

    • At the end of the session, the learner will be able to:

      1. Describe the contribution that neuroimaging has made to the understanding of how psychedelics work in the human brain.

      2. Discuss how neuroimaging methods can support future drug development efforts in the psychedelic field.

    • Panel On Group PAT 

    • At the end of the session, the learner will be able to:

      1. Understand some unique risks and benefits of psychedelic-assisted group therapy.

      2. Review highlights of the decades-long history of psychedelic-assisted group therapy.

    • Studies Of Adolescents And Psychedelics 

    • At the end of the session, the learner will be able to:

      1. Describe the safety considerations in adolescent psychedelic-assisted therapy.

      2. Discuss the role of the family in adolescent psychedelic-assisted therapy.

    • Postpartum Psychedelic Therapies Including MDMA-AT for PTSD and Opioid Use Disorder: Potentially Decreasing Intergenerational Trauma Transmission 

    • At the end of the session, the learner will be able to:

      1. Identify the roles of trauma and Post-Traumatic Stress Disorder (PTSD) as common root cause of addiction.

      2. Describe the hypothesized mechanisms of change involved in the use psychedelic assisted therapies for trauma and addiction including neurochemical and psychological pathways.

      3. Describe research study of MDMA Assisted Therapies for people 6-12 months after childbirth with PTSD and Opioid Use Disorder including hypothesized effect on maternal infant bonding and attachment.

    • Reimagining Recovery: Psychedelics, Substance Use, And The Future Of Healing 

    • At the end of the session, the learner will be able to:

      1. Identify two benefits and two risks to integrating psychedelic experiences into existing substances use disorder treatment approaches and recovery paradigms.

      2. Describe various cultural and systemic barriers to accessing psychedelic medicines to address substance use disorders and improve recovery processes.

    • Studies Of Microdosing Psychedelics 

    • At the end of the session, the learner will be able to:

      1. Describe recent evidence regarding the efficacy and safety of psilocybin microdosing for mild-to-moderate depression.

      2. Identify and discuss key methodological considerations and challenges in conducting clinical research trials involving psychedelic microdosing.

      3. Identify theoretical frameworks and proposed mechanisms underlying the psychological effects of psychedelic microdosing.

    • Studies Of Psychedelic-Assisted Therapy For Addiction Disorders 

    • At the end of the session, the learner will be able to:

      1. Explain how addiction impacts neurological processing in the brain using advanced brain imaging techniques.

      2. Discuss the potential for psychedelics to disrupt neurological patterns associated with addiction using the PsiloGambling study as a case study.

    • Unveiling Ketamine’s Neuroplastic Effects In Humans: A Multimodal Approach For A Multifaced Compound 

    • At the end of the session, the learner will be able to:

      1. Assess current evidence on the neuroplastic effects of psychedelics.

      2. Describe the novel results from Centre for Psychedelic Research Imperial College London on the neuroplastic effects of psychedelics in humans.

    • Studying The Mechanisms Of Ketamine In Animal Models 

    • At the end of the session, the learner will be able to:

      1. Identify the advantages of dendrimer-based drug delivery systems in targeting CNS disorders such as depression.

      2. Explain the mechanisms through which ketamine and its derivatives exert antidepressant effects in preclinical stress models.

    • What Is "Safe" And Who Gets To Decide? A Collaborative Assessment For Psychedelic-Assisted Therapy 

    • At the end of the session, the learner will be able to:

      1. Discuss the potential psychological, relational, and functional risks of psychedelic-assisted therapy, including those that may arise in medically supervised settings.

      2. Describe strategies to mitigate risk in psychedelic-assisted therapy, including attention to client preparation, set and setting, therapist training, and post-experience integration.

    • Studies Of End Of Life, Terminal Anxiety, And Grief With Psychedelic-Assisted Therapy 

    • At the end of the session, the learner will be able to:

      1. Describe the sociocultural frameworks of death and grief in the modern, Western world.

      2. Discuss the thematic Content of Psychedelic Experiences in the Context of Grief and Mechanisms of Therapeutic Change: The Role of Set and Setting.

      3. Describe the Meaning Reconstruction in Psychedelic Experience, Integration, and Grief Adaptation.

  • Final Submission

    Click 'Submit' once you have completed this form. You may 'Save' multiple times but only 'sbumit' once.
  • Should be Empty: